
News|Articles|October 1, 2002
Xendos study: Orlistat plus diet prevents, delays diabetes onset in obese patients
Orlistat (Xenical) in combination with diet and lifestyle changes significantly prevents obese patients from developing type 2 diabetes, say researchers involved in this 4-year study presented at the 9th International Congress on Obesity, Sao Paulo, Brazil. They add that this is the first time a weight loss drug has been shown to prevent or delay the onset of type 2 diabetes in an at-risk population.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Low uptake of shingles vaccine despite strong value proposition for older adults
5






















































